Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Misses Nasdaq Deadline to Retain Stock Listing, Though Continues Trading ...

NEW YORK, March 16 (GenomeWeb News) - Sequenom yesterday missed its Nasdaq-imposed minimum requirement for continued listing after failing to lift its shares above $1 for at least 10 consecutive trading days over the past six months.

 

As GenomeWeb News reported last September, the company had until March 15 to comply with the minimum bid requirement. The shares were trading at $.73 during the mid-afternoon.

 

Calls to Sequenom were not returned. Nasdaq officials deferred to the company.

 

In spite of the threat of imminent delisting, Sequenom shares rallied today on news of a new product launch.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.